These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 28231936)

  • 1. Effect of Linagliptin on Arterial
    de Boer SA; Heerspink HJ; Lefrandt JD; Hovinga-de Boer MC; van Roon AM; Juárez Orozco LE; Glaudemans AW; Kamphuisen PW; Slart RH; Mulder DJ
    J Am Coll Cardiol; 2017 Feb; 69(8):1097-1098. PubMed ID: 28231936
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of dipeptidyl peptidase 4 inhibition on inflammation in atherosclerosis: A
    Virta J; Hellberg S; Liljenbäck H; Ståhle M; Silvola JMU; Huusko J; Söderström M; Knuuti J; Nuutila P; Ylä-Herttuala S; Gomez MF; Roivainen A; Saraste A
    Atherosclerosis; 2020 Jul; 305():64-72. PubMed ID: 32386751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind, placebo-controlled dose-finding study of the dipeptidyl peptidase-4 inhibitor linagliptin in pediatric patients with type 2 diabetes.
    Tamborlane WV; Laffel LM; Weill J; Gordat M; Neubacher D; Retlich S; Hettema W; Hoesl CE; Kaspers S; Marquard J
    Pediatr Diabetes; 2018 Jun; 19(4):640-648. PubMed ID: 29171139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bullous Pemphigoid Associated With Linagliptin Treatment.
    Haber R; Fayad AM; Stephan F; Obeid G; Tomb R
    JAMA Dermatol; 2016 Feb; 152(2):224-6. PubMed ID: 26465961
    [No Abstract]   [Full Text] [Related]  

  • 5. Glyxambi--a new combination for type 2 diabetes.
    Med Lett Drugs Ther; 2015 Apr; 57(1467):65-6. PubMed ID: 25897551
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of Linagliptin on Vascular Function: A Randomized, Placebo-controlled Study.
    Baltzis D; Dushay JR; Loader J; Wu J; Greenman RL; Roustit M; Veves A
    J Clin Endocrinol Metab; 2016 Nov; 101(11):4205-4213. PubMed ID: 27583476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empagliflozin/Linagliptin: A Review in Type 2 Diabetes.
    Kim ES; Deeks ED
    Drugs; 2015 Sep; 75(13):1547-57. PubMed ID: 26323340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus.
    Retlich S; Duval V; Graefe-Mody U; Friedrich C; Patel S; Jaehde U; Staab A
    Clin Pharmacokinet; 2015 Jul; 54(7):737-50. PubMed ID: 25637172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No pleotropic effects of linagliptin on atherosclerotic plaques: Case closed.
    Al-Mallah MH; Hyafil F; Santulli G
    Atherosclerosis; 2020 Jul; 305():61-63. PubMed ID: 32561072
    [No Abstract]   [Full Text] [Related]  

  • 10. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
    Bonora E; Cigolini M
    Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):273-84. PubMed ID: 27038847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empagliflozin/linagliptin single-pill combination therapy for patients with type 2 diabetes mellitus.
    Jain RK
    Expert Opin Pharmacother; 2017 Apr; 18(6):545-549. PubMed ID: 28375658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular FDG uptake: further steps toward clinical acceptance.
    Bengel FM
    J Nucl Cardiol; 2008; 15(2):154-6. PubMed ID: 18371583
    [No Abstract]   [Full Text] [Related]  

  • 13. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
    Cooper ME; Perkovic V; McGill JB; Groop PH; Wanner C; Rosenstock J; Hehnke U; Woerle HJ; von Eynatten M
    Am J Kidney Dis; 2015 Sep; 66(3):441-9. PubMed ID: 25960304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sweet clarity: less invasive measures of hepatic glucose metabolism.
    Fine EJ; Lee DE; Hawkins M
    Gastroenterology; 2007 Feb; 132(2):794-7. PubMed ID: 17261305
    [No Abstract]   [Full Text] [Related]  

  • 15. The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Preserves Endothelial Function in Mesenteric Arteries from Type 1 Diabetic Rats without Decreasing Plasma Glucose.
    Salheen SM; Panchapakesan U; Pollock CA; Woodman OL
    PLoS One; 2015; 10(11):e0143941. PubMed ID: 26618855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered biodistribution of FDG in patients with type-2 diabetes mellitus.
    Ozguven MA; Karacalioglu AO; Ince S; Emer MO
    Ann Nucl Med; 2014 Jul; 28(6):505-11. PubMed ID: 24652347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.
    Heise T; Graefe-Mody EU; Hüttner S; Ring A; Trommeshauser D; Dugi KA
    Diabetes Obes Metab; 2009 Aug; 11(8):786-94. PubMed ID: 19476474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empagliflozin/Linagliptin: Combination therapy in patients with type 2 diabetes.
    Tan X; Hu J
    Ann Endocrinol (Paris); 2016 Oct; 77(5):557-562. PubMed ID: 27062036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arterial wall uptake of fluorodeoxyglucose on PET imaging in stable cancer disease patients indicates higher risk for cardiovascular events.
    Paulmier B; Duet M; Khayat R; Pierquet-Ghazzar N; Laissy JP; Maunoury C; Hugonnet F; Sauvaget E; Trinquart L; Faraggi M
    J Nucl Cardiol; 2008; 15(2):209-17. PubMed ID: 18371592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D™ trial.
    Groop PH; Cooper ME; Perkovic V; Sharma K; Schernthaner G; Haneda M; Hocher B; Gordat M; Cescutti J; Woerle HJ; von Eynatten M
    Diab Vasc Dis Res; 2015 Nov; 12(6):455-62. PubMed ID: 26224765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.